ArticleEuropean journal of clinical pharmacology2026
The role of Spanish clinical pharmacologists in economic evaluations of health technologies.
Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to describe the role and perceptions of clinical pharmacologists (CPs) in conducting economic evaluations of health technologies within the Spanish National Health System from a healthcare provider perspective.
methodsWe conducted a cross-sectional descriptive study using an online survey distributed to members of the Spanish Society of Clinical Pharmacology between September 2024 and September 2025. Eligible participants were CPs working within or linked to the Spanish National Health System. The questionnaire included four sections addressing respondent characteristics, direct involvement in economic evaluations, economic evaluations conducted by other professionals, and training and opinions. Data were analyzed using descriptive statistics.
resultsOf 106 eligible CPs working within or linked to the Spanish National Health System, 48 completed the survey (response rate: 45.3%). The mean age was 51 years, and 56.3% were women. More than half of respondents (54.2%) reported conducting or having conducted economic evaluations, mainly cost-effectiveness and cost-minimisation analyses, often in collaboration with other healthcare professionals. Results were integrated into care protocols in 15 cases, although follow-up and outcome verification were performed in 7 cases. Among CPs not directly involved, 63.7% reported that economic evaluations are conducted at their centres by other professionals. Despite 91.7% of respondents considered that economic evaluation of health technologies is an activity that should be conducted in their centres, and all considered that a CP should participate in these evaluations, only 35.4% felt sufficiently trained, while 77.1% expressed interest in further training.
conclusionAmong the surveyed CPs, there is active involvement and a high level of motivation to participate in economic evaluations of health technologies in Spain. Strengthening training opportunities and collaborative networks could enhance their contribution to value-based healthcare.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.